Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07034183
PHASE1

A First-in-Human Study of PRD001

Sponsor: PRD Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of PRD001 in healthy participants and to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of PRD001 in participants with borderline/mild hyper-LDL-cholesterolemia and mild fatty liver.

Official title: A First-in-Human Study of PRD001 in Healthy Participants, Assessment of Safety, Tolerability and Pharmacokinetics of Single/Multiple Doses

Key Details

Gender

MALE

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

86

Start Date

2025-06-19

Completion Date

2026-06

Last Updated

2025-07-30

Healthy Volunteers

Yes

Interventions

DRUG

PRD001

PRD001 capsules will be provided for oral administration

DRUG

Placebo

Placebo capsules will be provided for oral administration

Locations (1)

SOUSEIKAI Fukuoka Mirai Hospital

Fukuoka, Fukuoka, Japan